Skip to main content
Premium Trial:

Request an Annual Quote

Advion BioSciences Signs $9M Service Contract with Top-10 Pharma

NEW YORK, Dec. 16 (GenomeWeb News) - Advion BioSciences said today that it has signed a three-year mass spectrometry services contract worth $9 million with an undisclosed "top-10 pharmaceutical company."

Advion will provide scientists and instrumentation to support the pharmaceutical client's bioanalytical method development, method validation, and sample analysis programs, the company said.

The agreement also provides the client an option to increase its level of resources during the life of the contract.

Stephen Lowes, Advion's vice president of bioanalysis, called the deal the "first of its kind" for the company. "The contract offers a resource model that could be extended to other clients in an environment where top-tier bioanalytical experience is in high demand," he said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.